

Clinical Characteristics and Molecular Subtyping of *Vibrio vulnificus* Illnesses, Israel

Ronit Zaidenstein, Chantal Sadik, Larisa Lerner, Lea Valinsky June Kopelowitz, Ruth Yishai, Vered Agmon, Michele Parsons, Cheryl Bopp, and Miriam Weinberger

CME ACTIVITY

Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit. Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide CME for physicians. Medscape, LLC designates this educational activity for a maximum of 0.75 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation at <http://www.medscape.com/cme/eid>; (4) view/print certificate.

Learning Objectives

Upon completion of this activity, participants will be able to:

- List the predisposing factors for infections caused by *Vibrio vulnificus* biotypes 1 and 2.
- Identify the differences between infections caused by *V. vulnificus* biotypes 1 and 2 and biotype 3.
- Describe the types of fish associated with *V. vulnificus* biotype 3 infection.
- Describe the mortality associated with *V. vulnificus* biotype 3 infection.
- List the predictors of mortality in *V. vulnificus* biotype 3 infection.

Editor

Beverly Merritt, Technical Writer-Editor, *Emerging Infectious Diseases*. Disclosure: Beverly Merritt has disclosed no relevant financial relationships.

CME Author

Désirée Lie, MD, MEd, Clinical Professor, Family Medicine, University of California, Orange; Director, Division of Faculty Development, UCI Medical Center, Orange, California. Disclosure: Désirée Lie, MD, MEd, has disclosed no relevant financial relationships.

Authors

Disclosures: Ronit Zaidenstein, MD; Chantal Sadik, MD; Larisa Lerner, MD; Lea Valinsky, PhD; June Kopelowitz, PhD; Ruth Yishai, PhD; Vered Agmon, PhD; Michele Parsons, MS; Cheryl Bopp, MS; and Miriam Weinberger, MD, have disclosed no relevant financial relationships.

During 1996–1997, a new *Vibrio vulnificus* biotype 3, which caused severe soft tissue infection after fishbone injury, emerged in Israel. We conducted a follow-up study from 1998 through 2005 to assess changing trends, outcomes, and molecular relatedness of the implicated strains. A total of 132 cases (71% confirmed and 29% suspected) of *V. vulnificus* biotype 3 infection were found. Most infections (95%) were related to percutaneous fish exposure, mainly tilapia (83%) or common carp (13%). Bacteremia, altered immune status, and history of ischemic heart disease were identified as independent risk factors for death, which

reached a prevalence of 7.6%. Pulsed-field gel electrophoresis patterns of strains from 1998 through 2005 and from 1996 through 1997 showed a high degree of homogeneity and were distinct from those of *V. vulnificus* biotype 1. Infections caused by *V. vulnificus* biotype 3 continue to affect the public's health in Israel.

Vibrio vulnificus, a gram-negative bacterium of the family *Vibrionaceae*, is a worldwide inhabitant of salt water (1–3). *V. vulnificus* biotypes 1 and 2 are capable of causing severe human infection, including necrotizing fasciitis and septicemia; the death rate is substantial (4–6). Persons with chronic liver disease, particularly liver cirrhosis, are more prone to developing infection and at greatest risk for an adverse outcome (7,8). Other predisposing factors are iron overload and hemochromatosis and immunosuppression caused by steroid treatment, malignancy, HIV infection, renal failure, and organ transplantation (1,9,10).

Author affiliations: Assaf Harofe Medical Center, Zerifin, Israel (R. Zaidenstein, M. Weinberger); Israel Ministry of Health, Jerusalem, Israel (C. Sadik, L. Lerner, L. Valinsky, J. Kopelowitz, R. Yishai, V. Agmon); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M. Parsons, C. Bopp); and Tel Aviv University, Ramat Aviv, Israel (M. Weinberger)

DOI: 10.3201/eid1412.080499

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 12, December 2008

1875

Earning CME Credit

To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions and earn continuing medical education (CME) credit, please go to <http://www.medscape.com/cme/eid>. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers. You must be a registered user on Medscape.com. If you are not registered on Medscape.com, please click on the New Users: Free Registration link on the left hand side of the website to register. Only one answer is correct for each question. Once you successfully answer all post-test questions you will be able to view and/or print your certificate. For questions regarding the content of this activity, contact the accredited provider, CME@medscape.net. For technical assistance, contact CME@webmd.net. American Medical Association's Physician's Recognition Award (AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award, please refer to <http://www.ama-assn.org/ama/pub/category/2922.html>. The AMA has determined that physicians not licensed in the US who participate in this CME activity are eligible for *AMA PRA Category 1 Credits*[™]. Through agreements that the AMA has made with agencies in some countries, AMA PRA credit is acceptable as evidence of participation in CME activities. If you are not licensed in the US and want to obtain an AMA PRA CME credit, please complete the questions online, print the certificate and present it to your national medical association.

Article Title

Clinical Characteristics and Molecular Subtyping of *Vibrio vulnificus* Illnesses, Israel

CME Questions

1. Which of the following is least likely to be a predisposing factor for infections caused by *Vibrio vulnificus* biotypes 1 and 2?

- A. Anemia
- B. Organ transplantation
- C. HIV infection
- D. Chronic liver disease

2. Illness caused by *V. vulnificus* biotype 3 is best distinguished from that caused by biotypes 1 and 2 by which of the following?

- A. Method of transmission
- B. Genetic features
- C. Geographic distribution
- D. All of the above

3. Which of the following is the primary fish involved in *V. vulnificus* biotype 3 infection?

- A. Gray mullet
- B. Tilapia
- C. Salmon
- D. Sea bass

4. Which of the following best describes the mortality associated with *V. vulnificus* biotype 3 infection as reported in Israel?

- A. 1.0%
- B. 2.3%
- C. 5.2%
- D. 7.5%

5. Which of the following is least likely to be an independent predictor of mortality for *V. vulnificus* biotype 3 infection?

- A. Bacteremia
- B. Ischemic heart disease
- C. Sex
- D. Altered immune status

Activity Evaluation

1. The activity supported the learning objectives.

Strongly Disagree

1

2

3

4

Strongly Agree

5

2. The material was organized clearly for learning to occur.

Strongly Disagree

1

2

3

4

Strongly Agree

5

3. The content learned from this activity will impact my practice.

Strongly Disagree

1

2

3

4

Strongly Agree

5

4. The activity was presented objectively and free of commercial bias.

Strongly Disagree

1

2

3

4

Strongly Agree

5

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 12, December 2008

1985